Influence of clinical pharmaceutical care on medication compliance and treatment effect in Helicobacter pylori positive peptic ulcer outpatients

doi:10.12092/j.issn.1009-2501.2018.02.016

Abstract

Abstract:

AIM: To assess the influence of clinical pharmaceutical care on medication compliance and treatment effect in Helicobacter pylori (H.pylori) eradication in outpatients with peptic ulcer. METHODS: Ninety-six outpatients with H.pylori positive peptic ulcer from July 2015 to June 2016 were prospectively collected and were randomly divided into control group and intervention group. Patients in the control group were given the traditional outpatient service. The intervention group patients received pharmaceutical education and follow-up by clinical pharmacist. Medication compliance and gastrointestinal symptom were assessed in both groups before and after H.pylori eradication therapy. H.pylori eradication rates of all patients were tested by 14C urea breath test after the end of stopping all medicines for at least 4 weeks. RESULTS: The score and the improvement of compliance with medication of intervention group patients were significantly higher than those of the control group (3.73 vs.2.58, 1.71 vs.0.44, P<0.01). 81.25% of patients in intervention group and 60.42% of patients in control group took all prescribed doses. The difference was statistically different（P<0.05）. Forty-four patients of the intervention group and thirty-six patients in the control group reported less gastrointestinal symptoms (91.67% vs.75.00%, P<0.05). The H.pylori eradication rate of the intervention group was significantly higher than that of the control group (91.67% vs.72.92%, P<0.05). CONCLUSION: Clinical pharmaceutical care has a significant effect on H.pylori eradication rate, medication compliance and the improvement of gastrointestinal symptom.

Key words: clinical pharmaceutical care, Helicobacter pylori eradication, peptic ulcer, medication compliance

CLC Number:

R969.3

LI Jingjing, YU Yanxia, TANG Lian, ZHANG Jinkun, YU Qiang, SHANG Erning. Influence of clinical pharmaceutical care on medication compliance and treatment effect in Helicobacter pylori positive peptic ulcer outpatients[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(2): 199-204.

References

［1］中华消化杂志编委会. 消化性溃疡诊断与治疗规范（2016年，西安）［J］. 中华消化杂志, 2016,36(8):508-513.
［2］Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report［J］. Gut, 2012,61(5):646-664.
［3］Lanas A, Chan FK. Peptic ulcer disease［J］. Lancet, 2017(Feb 23). doi: 10.1016/S0140-6736(16)32404-7.
［4］胡伏莲. 重视幽门螺杆菌感染根除治疗中的几个问题［J］. 中华医学杂志, 2013,93(44):3489-3490.
［5］戴巧君, 舒小莉. 影响幽门螺杆菌阳性消化性溃疡患者病原菌根除效果的相关因素分析［J］. 中国现代医生, 2013,51(12):9-11.
［6］姒健敏, 王杭勇, 蔡建庭, 等. 中国人溃疡病流行状况及其治疗依从性［J］. 中华内科杂志, 2000, 39(3): 153-155.
［7］Laskin DM. Following the doctor`s orders［J］. J Oral Maxillofac Surg, 1994, 52(5): 437.
［8］Svedlund J, Sjodin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease［J］. Dig Dis Sci, 1988,33(2):129-134.
［9］Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence［J］. Med Care, 1986,24(1):67-74.
［10］虞燕霞, 朱莉红, 唐莲, 等. 药学服务干预对高脂血症患者用药依从性、治疗效果及颈动脉粥样斑块的影响分析［J］. 中国药学杂志, 2014, 49(19): 1760-1762.
［11］Al-Eidan FA, McElnay JC, Scott MG, et al. Management of Helicobacter pylori eradication-the influence of structured counselling and follow-up［J］. Br J Clin Pharmacol, 2002, 53(2): 163-171.
［12］Funakoshi R, Yokoyama H, Kawai N, et al. Effect of pharmaceutical care on diagnosis based on assessment of 13C-urea breath test for Helicobacter pylori infection［J］. YAKUGAKU ZASSHI, 2012, 132(5): 601-607.
［13］李晓娟, 李哲轩, 汤富兵, 等. 幽门螺杆菌根除效果影响因素分析［J］. 中华肿瘤防治杂志, 2015, 22(15): 1165-1169.
［14］Shahid SK. Novel anti-Helicobacter pylori therapies［J］. Pharm Pat Anal, 2014, 3(4): 411-427.
［15］Greenberg ER, Anderson GL, Morgan DR, et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial［J］. Lancet, 2011, 378(9790): 507-514.
［16］Wang CH, Liao ST, Yang J, et al. Effects of daily telephone-based re-education before taking medicine on Helicobacter pylori eradication: A prospective single-center study from China［J］. World J Gastroenterol, 2015, 21(39): 11179-11184.
［17］彭昕, 宋丽秀, 陈卫刚, 等. 电话随访对幽门螺杆菌感染患者服药依从性及根除率的影响［J］. 中南大学学报（医学版）, 2017, 42(3): 308-312.
［18］王艳，周惠琴，唐文.苏州市胃肠病患者幽门螺杆菌耐药分析［J］.中国公共卫生，2010,26（1）：122-123.

[1]	LI Guo-zhu, XIE Hai-tang, CHEN Bai-feng, WANG Hao, SUN Xiao-tian. A survey on adult medication compliance and its influencing factors analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 47-50.
[2]	GUO Gan-hua,WANG Fang-fang,SONG feng-qian,SHEN Jian-chong,LU Bei-jun,ZHOU Chun-fei,YE Shu-yun. Clinical research of teprenone to prevent recurrence of NSAIDs-related ulcer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 806-811.
[3]	JU Jing. Experimental study on the protective effect of total glycosides of Zhizi for ulceration in pylorus ligature rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(10): 1106-1109.
[4]	LIANG Xiao-qing, DING Hong-ming, LI Ai-guo, CHANG Sheng, WANG Xian-guo, HE Jun, ZHAO Yi. Clinical efficacy and safety evaluation of Jianweiyuyangpian in treatment of 314 patients with peptic ulcer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 835-837.
[5]	CHEN Yong-rong. Meta-analysis of effectiveness of omeprazole and otherdrugs in treatment of active peptic ulcerand bleeding [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(12): 1420-1422.
[6]	LI Jian-Chun, LI Juan, TIAN Xue-Feng. Meta-analysis of effectiveness ofPantoprazole and other drugs in treatment ofPatients with activePeptic ulcer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(6): 696-698.
[7]	CAI Ning, WANG Hong-Xin, YAN Fei, WANG Zhi-Yi, YU Xiang-Guo, TANG Yi-Chao. Efficacy of deproteinised calf blood extract in treatment of patients with peptic ulcer disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(3): 314-316.